Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of BIIB076 in Healthy Volunteers and Alzheimer's Disease
NCT03056729Phase 1Completed
- Sponsor
- Biogen
- Start
- Feb 2017
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BIIB076 in Alzheimer's disease (AD) (6 cohorts), sponsored by Biogen. Primary endpoint: Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Feb 2017; status: completed.
02
Drugs
BIIB076
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03056729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03056729.